$0.77
3.71% yesterday
Nasdaq, Aug 11, 10:13 pm CET
ISIN
US8693671021
Symbol
STRO

Sutro Biopharma, Inc. Stock price

$0.77
+0.01 1.46% 1M
-0.85 52.46% 6M
-1.07 58.01% YTD
-2.47 76.15% 1Y
-6.03 88.64% 3Y
-7.73 90.91% 5Y
-14.43 94.92% 10Y
-14.43 94.92% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.03 3.71%
ISIN
US8693671021
Symbol
STRO
Industry

Key metrics

Basic
Market capitalization
$65.5m
Enterprise Value
$-139.6m
Net debt
positive
Cash
$205.1m
Shares outstanding
84.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 1.1
EV/Sales
negative | negative
EV/FCF
0.6
P/B
negative
Financial Health
Equity Ratio
11.5%
Return on Equity
-510.0%
ROCE
-88.0%
ROIC
-408.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$104.5m | $59.6m
EBITDA
$-158.1m | $-160.1m
EBIT
$-165.6m | $-150.5m
Net Income
$-208.7m | $-169.8m
Free Cash Flow
$-252.0m
Growth (TTM | estimate)
Revenue
-38.3% | -4.0%
EBITDA
-59.5% | 30.8%
EBIT
-56.0% | 36.9%
Net Income
-67.7% | 25.4%
Free Cash Flow
-224.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-151.3% | -268.9%
EBIT
-158.5%
Net
-199.8% | -285.0%
Free Cash Flow
-241.2%
More
EPS
$-2.5
FCF per Share
$-3.0
Short interest
4.4%
Employees
310
Rev per Employee
$200.0k
Show more

Is Sutro Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Sutro Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Sutro Biopharma, Inc. forecast:

10x Buy
63%
5x Hold
31%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a Sutro Biopharma, Inc. forecast:

Buy
63%
Hold
31%
Sell
6%

Financial data from Sutro Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
104 104
38% 38%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 47 47
18% 18%
45%
- Research and Development Expense 223 223
2% 2%
214%
-158 -158
60% 60%
-151%
- Depreciation and Amortization 7.47 7.47
6% 6%
7%
EBIT (Operating Income) EBIT -166 -166
56% 56%
-158%
Net Profit -209 -209
68% 68%
-200%

In millions USD.

Don't miss a Thing! We will send you all news about Sutro Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sutro Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Neutral
GlobeNewsWire
3 months ago
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Neutral
GlobeNewsWire
3 months ago
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
More Sutro Biopharma, Inc. News

Company Profile

Sutro Biopharma Inc. engages in the drug discovery, development, and manufacturing of pharmaceutical products. It focuses on next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jane Chung
Employees 310
Founded 2003
Website www.sutrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today